Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.

Gregorič N, Šikonja J, Janež A, Jensterle M

Diabetes, obesity & metabolism7 Nov 2024Cited by 33 (Europe PMC)

PMID39511836PMCIDPMC11701185DOI10.1111/dom.16042PepBankPUB-39511836

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with type 2 diabetes, obesity and functional hypogonadism, semaglutide gave a higher number of morphologically normal sperm than testosterone undecanoate.
In plain wordsIn men with type 2 diabetes, obesity and low testosterone, semaglutide gave more normally shaped sperm than testosterone injections.
Peptide
Semaglutide
Outcome
IncreaseMorphologically normal sperm versus testosterone therapy
Study
n = 25
Comparator
Testosterone undecanoate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1 mg/week · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared to TRT, the SEMA group had a significantly higher number of morphologically normal sperm, sperm concentration and total number.
1 context sentence(design, population, supporting numbers)
Summary · context
We designed a randomised open-label trial in 25 men with type 2 diabetes (aged 50 [46-60] years, BMI 35.9 [32.8-38.7] kg/m²) and FH randomised to semaglutide (SEMA) 1 mg/week or intramuscular testosterone undecanoate (TRT) 1000 mg/10-12 weeks for 24 weeks.
Report a problemFND-3951183602
02HumanRandomized controlled trialEfficacy outcome
In men with type 2 diabetes, obesity and functional hypogonadism, sperm concentration was higher with semaglutide than with testosterone undecanoate.
In plain wordsIn men with type 2 diabetes, obesity and low testosterone, sperm concentration was higher with semaglutide than with testosterone injections.
Peptide
Semaglutide
Outcome
IncreaseSperm concentration versus testosterone therapy
Study
n = 25
Comparator
Testosterone undecanoate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1 mg/week · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared to TRT, the SEMA group had a significantly higher number of morphologically normal sperm, sperm concentration and total number.
1 context sentence(design, population, supporting numbers)
Summary · context
We designed a randomised open-label trial in 25 men with type 2 diabetes (aged 50 [46-60] years, BMI 35.9 [32.8-38.7] kg/m²) and FH randomised to semaglutide (SEMA) 1 mg/week or intramuscular testosterone undecanoate (TRT) 1000 mg/10-12 weeks for 24 weeks.
Report a problemFND-3951183603
03HumanRandomized controlled trialEfficacy outcome
In men with type 2 diabetes, obesity and functional hypogonadism, total sperm number was higher with semaglutide than with testosterone undecanoate.
In plain wordsIn men with type 2 diabetes, obesity and low testosterone, total sperm number was higher with semaglutide than with testosterone injections.
Peptide
Semaglutide
Outcome
IncreaseTotal sperm number versus testosterone therapy
Study
n = 25
Comparator
Testosterone undecanoate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1 mg/week · 24 weeksAs given in this study (human).
Source sentences
Summary
Compared to TRT, the SEMA group had a significantly higher number of morphologically normal sperm, sperm concentration and total number.
1 context sentence(design, population, supporting numbers)
Summary · context
We designed a randomised open-label trial in 25 men with type 2 diabetes (aged 50 [46-60] years, BMI 35.9 [32.8-38.7] kg/m²) and FH randomised to semaglutide (SEMA) 1 mg/week or intramuscular testosterone undecanoate (TRT) 1000 mg/10-12 weeks for 24 weeks.
Report a problemFND-3951183604
04HumanRandomized controlled trialEfficacy outcome
In men with type 2 diabetes, obesity and functional hypogonadism, semaglutide increased morphologically normal sperm from baseline to week 24.
In plain wordsIn men with type 2 diabetes, obesity and low testosterone, semaglutide raised the share of normally shaped sperm compared with before treatment.
Peptide
Semaglutide
Outcome
IncreaseMorphologically normal sperm, change from baseline
Study
n: not reported in source
Comparator
Baseline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1 mg/week · 24 weeksAs given in this study (human).
Measurements
Morphologically normal sperm
2%
baseline
Morphologically normal sperm
4%
end of study
Source sentences
Summary
In the SEMA group, there was a significant increase in morphologically normal sperm from baseline to the end of the study (2% [2; 3.5] vs. 4% [2; 5.5]; p = 0.012)
1 context sentence(design, population, supporting numbers)
Summary · context
We designed a randomised open-label trial in 25 men with type 2 diabetes (aged 50 [46-60] years, BMI 35.9 [32.8-38.7] kg/m²) and FH randomised to semaglutide (SEMA) 1 mg/week or intramuscular testosterone undecanoate (TRT) 1000 mg/10-12 weeks for 24 weeks.
Report a problemFND-3951183601
05HumanRandomized controlled trialEfficacy outcome
In men with type 2 diabetes, obesity and functional hypogonadism, total testosterone rose from baseline in the semaglutide group, as it did in the testosterone group.
In plain wordsIn men with type 2 diabetes, obesity and low testosterone, total testosterone rose with semaglutide, as it did with testosterone treatment.
Peptide
Semaglutide
Outcome
IncreaseTotal testosterone, change from baseline
Study
n: not reported in source
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1 mg/week · 24 weeksAs given in this study (human).
Source sentences
Summary
Both groups experienced an increase in total testosterone and improvement in the AMS score, whereas the IIEF-15 score significantly improved only in the TRT group.
1 context sentence(design, population, supporting numbers)
Summary · context
We designed a randomised open-label trial in 25 men with type 2 diabetes (aged 50 [46-60] years, BMI 35.9 [32.8-38.7] kg/m²) and FH randomised to semaglutide (SEMA) 1 mg/week or intramuscular testosterone undecanoate (TRT) 1000 mg/10-12 weeks for 24 weeks.
Report a problemFND-3951183605
06HumanRandomized controlled trialEfficacy outcome
In men with type 2 diabetes, obesity and functional hypogonadism, the Aging Symptoms in Men score improved in the semaglutide group, as it did in the testosterone group.
In plain wordsIn men with type 2 diabetes, obesity and low testosterone, aging-symptom scores improved with semaglutide, as they did with testosterone treatment.
Peptide
Semaglutide
Outcome
DecreaseAMS score (aging symptoms), change from baseline
Study
n: not reported in source
Comparator
Baseline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1 mg/week · 24 weeksAs given in this study (human).
Source sentences
Summary
Both groups experienced an increase in total testosterone and improvement in the AMS score
1 context sentence(design, population, supporting numbers)
Summary · context
We designed a randomised open-label trial in 25 men with type 2 diabetes (aged 50 [46-60] years, BMI 35.9 [32.8-38.7] kg/m²) and FH randomised to semaglutide (SEMA) 1 mg/week or intramuscular testosterone undecanoate (TRT) 1000 mg/10-12 weeks for 24 weeks.
Report a problemFND-3951183606
07HumanRandomized controlled trialEfficacy outcome
In men with type 2 diabetes, obesity and functional hypogonadism, the IIEF-15 score did not improve significantly in the semaglutide group; it improved only in the testosterone group.
In plain wordsIn men with type 2 diabetes, obesity and low testosterone, erectile function scores did not improve significantly with semaglutide, but did with testosterone.
Peptide
Semaglutide
Outcome
No significant changeIIEF-15 score (erectile function), change from baseline
Study
n: not reported in source
Comparator
Baseline
Outcome group
Sexual function · Reproductive and sexual health
Studied dose
1 mg/week · 24 weeksAs given in this study (human).
Source sentences
Summary
whereas the IIEF-15 score significantly improved only in the TRT group.
1 context sentence(design, population, supporting numbers)
Summary · context
We designed a randomised open-label trial in 25 men with type 2 diabetes (aged 50 [46-60] years, BMI 35.9 [32.8-38.7] kg/m²) and FH randomised to semaglutide (SEMA) 1 mg/week or intramuscular testosterone undecanoate (TRT) 1000 mg/10-12 weeks for 24 weeks.
Report a problemFND-3951183607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT06489457

The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity

University Medical Centre Ljubljanan = 2520 Sept 2020 to 30 Jun 2023

Type 2 Diabetes Mellitus · Obesity · Functional Hypogonadism

Trial page ClinicalTrials.govUpdated 8 Jul 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.